Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity

被引：40

作者：

Major P.P. ^{[1
]}

Cook R.J. ^{[2
]}

Lipton A. ^{[3
]}

Smith M.R. ^{[4
]}

Terpos E. ^{[5
]}

Coleman R.E. ^{[6
]}

机构：

[1] McMaster University, Juravinski Cancer Centre, Hamilton, Ontario

[2] University of Waterloo, Waterloo, Ontario

[3] Penn State Cancer Center, Milton S. Hershey Medical Center, Hershey, Pennsylvania

[4] Massachusetts General Hospital, Boston, Massachusetts

[5] 251 General Airforce Hospital, Athens

[6] Cancer Research Centre, Weston Park Hospital, Academic Unit of Oncology, Sheffield

来源：

BMC Cancer | / 9卷 / 1期

关键词：

Breast Cancer; Bone Metastasis; Zoledronic Acid; Bone Lesion; Pamidronate;

D O I：

10.1186/1471-2407-9-272

中图分类号：

学科分类号：

摘要：

Background: Bone metastases are a common cause of skeletal morbidity in patients with advanced cancer. The pattern of skeletal morbidity is complex, and the number of skeletal complications is influenced by the duration of survival. Because many patients with cancer die before trial completion, there is a need for survival-adjusted methods to accurately assess the effects of treatment on skeletal morbidity. Methods: Recently, a survival-adjusted cumulative mean function model has been generated that can provide an intuitive graphic representation of skeletal morbidity throughout a study. This model was applied to the placebo-control arm of a pamidronate study in patients with malignant bone disease from breast cancer. Results: Analysis by bone lesion location showed that spinal metastases were associated with the highest cumulative mean incidence of skeletal-related events (SREs), followed by chest and pelvic metastases. Metastases located in the extremities were associated with an intermediate incidence of SREs, and those in the skull were associated with the lowest incidence of SREs. Conclusion: Application of this model to data from the placebo arm of this trial revealed important insight into the natural history of skeletal morbidity in patients with bone metastases. Based on these observations, treatment for the prevention of SREs is warranted regardless of lesion location except for metastases on the skull. © 2009 Major et al; licensee BioMed Central Ltd.

引用

共 30 条

[1]

Coleman R.E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treat Rev, 27, pp. 165-176, (2001)

[2]

Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J., Cancer statistics, 2007, CA Cancer J Clin, 57, pp. 43-66, (2007)

[3]

Coleman R.E., Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin Cancer Res, 12, 20 PART 2, (2006)

[4]

Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M., Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group, J Clin Oncol, 16, pp. 593-602, (1998)

[5]

Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., Reitsma D.J., Heffernan M., Seaman J.J., Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials, Cancer, 88, pp. 1082-1090, (2000)

[6]

Rosen L.S., Gordon D., Tchekmedyian N.S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., De Souza P., Zheng M., Urbanowitz G., Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial, Cancer, 100, pp. 2613-2621, (2004)

[7]

Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., Zheng M., Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, pp. 879-882, (2004)

[8]

Kaminski M., Rosen L.S., Gordon D., Zheng M., Hei Y.-.M., Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications., Poster presented at: Primary Therapy of Early Breast Cancer 9th International Conference

[9]

26-29 January 2005

[10]

St. Gallen, Switzerland

← 1 2 3 →